Immunophotonics wins new U.S. patent for IP-001 cancer combo therapy
Immunophotonics says the U.S. Patent and Trademark Office issued a new patent covering IP-001 combined with immune-checkpoint inhibitors, extending protection into 2041. The company says the grant adds to patent coverage already secured in China and much of Europe, with Canada still pending final issuance.
Why it matters: - The new U.S. patent broadens legal protection around Immunophotonics' lead asset, IP-001, and its planned use with checkpoint inhibitors. - The patent term extension into 2041 lengthens the window for potential commercialization of the combination approach. - The grant adds another layer to a cross-border patent estate spanning the U.S., China, Europe and, pending final issuance, Canada.
What happened: - The U.S. Patent and Trademark Office issued U.S. Patent No. 12,797,407, titled “Semi-Synthetic Biopolymers for Use in Stimulating the Immune System.” - The patent covers IP-001 in combination with immune-checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 therapies. - The patent received a 584-day Patent Term Adjustment, extending its term into 2041. - Immunophotonics says the U.S. filing is the national-stage application from the same patent family previously granted in China and much of Europe earlier in 2026. - The company also has received a notice of allowance from the Canadian Intellectual Property Office for the Canadian national-stage application, with final issuance still pending.
The details: - IP-001 is a proprietary glycan polymer designed to create tumor antigen depots and stimulate the immune system. - The therapy is intended to prolong the availability of tumor antigens released by ablation, recruit and activate innate immune cells, increase antigen uptake and promote an adaptive anti-tumor response. - Immunophotonics says IP-001 is being assessed in multiple clinical trials across solid tumor indications. - The company describes IP-001 as the first asset from its intellectual property platform and a core part of its Interventional Immuno-Oncology approach. - Immunophotonics combines routine energy therapies such as ablation or radiation with injection of proprietary immunostimulatory drug candidates. - The company says that approach is designed to help destroy circulating tumor cells and micro-metastases left behind after local ablation. - The company’s headquarters are in St. Louis, Missouri, and its European headquarters are in Bern, Switzerland. - More information is available in the company's announcement. - The company also listed social accounts on LinkedIn, Instagram and X at the end of the release.
Between the lines: - The patent coverage around checkpoint inhibitor combinations suggests Immunophotonics is positioning IP-001 for use in broader immuno-oncology regimens, not just as a standalone adjunct to tumor ablation. - The layered patent strategy across major markets signals an effort to protect both near-term clinical development and longer-term partnering or commercial value. - The release pairs the IP update with a message that intellectual property remains central as the company advances IP-001 through development.
What's next: - Immunophotonics said it will continue evaluating IP-001 across multiple solid tumor indications. - The company also said it will keep strengthening its intellectual property foundation while advancing clinical programs and exploring combinations with other immuno-oncology assets. - Final Canadian patent issuance remains pending.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
North America Today
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.